Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
33.20 MXN
7.33 B MXN
63.83 B MXN
154.44 M
About HIKMA PHARMACEUTICALS ORD GBP0.10
Sector
Industry
CEO
Riad Mishlawi
Website
Headquarters
London
Founded
1978
ISIN
GB00B0LCW083
FIGI
BBG00F5P2LS6
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.
Is this Hikma's cue for a break out?Will Hikma break out after a 5 year H&S pattern,
now that it's making progress in the Covid-19 vaccine business?
Hikma Pharmaceuticals - Injecting some bullish momentum.Buy Hikma Pharmaceuticals (HIK.L)
Hikma Pharmaceuticals PLC develops, manufactures, and markets pharmaceutical products. The Company offers branded and non-branded generic and in-licensed pharmaceutical products. Hikma Pharmaceuticals serves customers worldwide.
Market Cap: £4.79Billion
The lo
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of HIK/N is 538.75 MXN — it has increased by 113.41% in the past 24 hours. Watch HIKMA PHARMACEUTICALS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange HIKMA PHARMACEUTICALS stocks are traded under the ticker HIK/N.
We've gathered analysts' opinions on HIKMA PHARMACEUTICALS future price: according to them, HIK/N price has a max estimate of 784.33 MXN and a min estimate of 550.44 MXN. Watch HIK/N chart and read a more detailed HIKMA PHARMACEUTICALS stock forecast: see what analysts think of HIKMA PHARMACEUTICALS and suggest that you do with its stocks.
HIK/N reached its all-time high on May 28, 2025 with the price of 538.75 MXN, and its all-time low was 252.45 MXN and was reached on Nov 16, 2017. View more price dynamics on HIK/N chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
HIK/N stock is 53.14% volatile and has beta coefficient of 0.88. Track HIKMA PHARMACEUTICALS stock price on the chart and check out the list of the most volatile stocks — is HIKMA PHARMACEUTICALS there?
Today HIKMA PHARMACEUTICALS has the market capitalization of 118.14 B, it has increased by 1.63% over the last week.
Yes, you can track HIKMA PHARMACEUTICALS financials in yearly and quarterly reports right on TradingView.
HIKMA PHARMACEUTICALS is going to release the next earnings report on Aug 7, 2025. Keep track of upcoming events with our Earnings Calendar.
HIK/N net income for the last half-year is 2.69 B MXN, while the previous report showed 4.14 B MXN of net income which accounts for −35.14% change. Track more HIKMA PHARMACEUTICALS financial stats to get the full picture.
HIKMA PHARMACEUTICALS dividend yield was 3.11% in 2024, and payout ratio reached 48.77%. The year before the numbers were 3.17% and 81.97% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jun 12, 2025, the company has 9.5 K employees. See our rating of the largest employees — is HIKMA PHARMACEUTICALS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HIKMA PHARMACEUTICALS EBITDA is 16.44 B MXN, and current EBITDA margin is 25.71%. See more stats in HIKMA PHARMACEUTICALS financial statements.
Like other stocks, HIK/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HIKMA PHARMACEUTICALS stock right from TradingView charts — choose your broker and connect to your account.